Oncology MRI

Is it a thoughtless verbal reflex or a failure to go beyond a surface read of imaging?

Catch up on the top radiology content of the past week.

Given the challenges with the shortage of the iodinated contrast agent Omnipaque, national and state organizations have issued suggested risk mitigation and conservation strategies to reprioritize imaging needs during this temporary shortage.

What is the diagnosis?

Offering integrated artificial intelligence (AI) and seamless multi-nuclei imaging capabilities, the new magnetic resonance imaging (MRI) system reportedly enhances image quality and workflow efficiency.

Review the top radiology content from the past week.

While there can be an array of challenges in outsourcing night coverage to teleradiology service providers, due diligence with contract terms can help mitigate costs and increase flexibility if radiology practices decide to switch teleradiology providers down the line.

Could an emerging modality provide a viable alternative to gadolinium-based contrast agents (GBCAs) in this high-risk patient population?

Review top radiology content from the week.

Validating a prognostic scoring system for locoregional recurrence risk in post-mastectomy patients with varying levels of axillary lymph node involvement, emerging research suggests patients with intermediate risk for breast cancer recurrence could benefit from post-mastectomy radiotherapy.

Review top radiology content from the week.

In a recent video interview, Arun Krishnaraj, MD, MPH and David Larson, MD, MBA, discussed the continued use of physical media to transport medical images between different health-care facilities, resulting inefficiencies and delays with patient care, and the initiative to create a linked multi-hub model to end this dated practice once and for all.

In addition to segmentation of the prostate, the artificial intelligence (AI)-enabled advance reportedly facilitates PI-RADS scoring by assessing the size and intensity of possible lesions.

Review top radiology content from the week.

Review top radiology content from the week.

The new whole-body magnetic resonance imaging (MRI) platform reportedly offers enhanced image quality and increased patient comfort.

Given the broad range of fibrocystic changes, the authors of a recent study suggest that more precise diagnosis of breast MRIs could significantly reduce unnecessary biopsy procedures.

Study findings further highlight the central role of PET/CT in disease response after CAR-T cell therapy.

Diffusion-weighted imaging may be useful as a safe and effective screening tool to supplement mammography in women with dense breast tissues.

PSMA PET is highly robust in identifying prostate cancer lesions which are otherwise deemed unremarkable.

Multiparametric MRI can detect pathologic complete response after neoadjuvant therapy in patients with esophageal squamous cell carcinoma.

Breast ultrasound/MRI fusion significantly improves localization of incidentally detected MRI lesions which are occult on an initial ultrasound survey alone.

The combination approach may significantly reduce over-detection while providing noninferior detection of clinically significant prostate cancer.

The algorithm is the first step towards developing an artificial intelligence-augmented radiology workflow that can support image interpretation to improve diagnosis and prognosis.

Training sets from different vendors may be required to ensure scanner-specific sensitivity.

The clear cell likelihood score can help providers determine the growth rate of masses that could be cancerous.

Including MRI leads to more quality-adjusted life years.

The potential opportunities are numerous for virtual biopsies, radiomics, and radiogenomics.

Relying on MRI images rather than PSA screening can reduce unnecessary biopsies and identification of clinically insignificant cancers.

Using a deep convolutional neural network can improve providers’ ability to predict how patients with hepatocellular carcinoma will respond to Y90-RE treatment, enabling them to offer additional therapies, if necessary.